TRX 103
Alternative Names: TRX-103Latest Information Update: 10 Sep 2026
At a glance
- Originator Tr1X
- Class Gene therapies; Regulatory T lymphocyte cell therapies
- Mechanism of Action Interleukin-10 expression stimulants; Regulatory T-lymphocyte replacements
-
Orphan Drug Status
Yes - Graft-versus-host disease
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Crohn's disease; Graft-versus-host disease
- Preclinical Immune-mediated uveitis; Inflammatory bowel diseases
Most Recent Events
- 03 Sep 2026 TRX 103 receives Fast Track designation for Crohn's disease [Parenteral] (Treatment-experienced) in USA before September 2026 (TR1X pipeline, September 2026)
- 27 Apr 2026 Updated adverse events, pharmacodynamics data from a phase I trial in Graft versus host disease released by Tr1X
- 29 Mar 2026 TRX 103 receives Orphan Drug status for Graft-versus-host disease (Prevention) in USA (Tr1X Bio pipeline, March 2026)